Spica Therapeutics has secured €10 million in a Seed financing round, co-led by Bioqube Ventures and Flanders Future Tech Fund, to advance its macrophage-targeted therapies.

Target Information

Spica Therapeutics is a cutting-edge biotechnology firm headquartered in Antwerp, Belgium, with a research facility located in Aarhus, Denmark. The company specializes in advancing macrophage-targeted therapies to address unmet medical needs in oncology and fibroinflammatory diseases. Utilizing its proprietary functional macrophage fingerprinting technology, Spica aims to identify and selectively target disease-relevant macrophage subsets, fostering innovative treatment approaches.

Founded on groundbreaking research from prestigious institutes like the University of Aarhus and INSERM, Spica's development pipeline includes several lead programs focused on depleting anti-CD163 monoclonal antibodies. The successful closing of a €10 million Seed financing round is expected to propel these programs into early Investigational New Drug (IND) enabling studies.

Industry Overview in Belgium

Belgium boasts a robust life sciences sector characterized by a rich tapestry of innovative startups and established biotechnology companies. This flourishing ecosystem is cultivated through strong academic institutions, rese